Mountain Crest Acquisition Corp. V Overview
Pro stress-test →Mountain Crest Acquisition Corp. V (MCAG) is a special purpose acquisition company founded in April 2021 and incorporated in Delaware for the purpose of effecting a business combination. The company completed its IPO in November 2021, raising $69 million. MCAG signed a definitive agreement with CUBEBIO Co., Ltd., an in-vitro diagnostic company with early-stage cancer detection technology, in August 2024.
Strategic Profile
Pro stress-test →The SPAC focuses its search on private companies in North America and Asia Pacific regions. The company has repeatedly extended its business combination deadline, most recently to November 16, 2026, using sponsor deposits and promissory notes to fund operations. In December 2025, MCAG issued an unsecured promissory note of up to $500,000 to its sponsor to maintain liquidity as the CUBEBIO merger pursues completion.
Competitive Landscape
Pro stress-test →MCAG does not compete directly; it is a blank-check acquisition vehicle seeking targets in biotech/diagnostics. Once merged, the combined entity would compete in early-stage cancer detection with diagnostics companies and laboratory services. Comparable SPACs active in healthcare/biotech include General Purpose Acquisition vehicles and specialized healthcare SPACs.
Industry Context
Mountain Crest Acquisition Corp. V operates in SPACs and blank-check acquisition vehicles.
Key facts
Founded: 2021 · Headquarters: New York, US · Employees: N/A · Revenue: N/A · Market cap: N/A